Company intelligence / Profile preview

Favrille, Inc.

San Diego, California, United Stateszoominfo.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Favrille completed a Phase 3 registration trial for Specifid (also known as FavId) in follicular B-cell NHL with 349 patients randomized. The trial was conducted at 67 centers in the U.S. and enrolled both treatment-naive and previously treated patients, with a larger treatment-naive population (78%)[1].

Therapeutic areas: Oncology
Modalities: Immunotherapiespatient-specific active immunotherapiesidiotype vaccines
Industry: Biomedical IT and Biomedical Data Platforms

Drug pipeline

2 assets

FavId

Phase 3

Indications: Follicular B-cell non-Hodgkin lymphoma, B-cell non-Hodgkin lymphoma

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Favrille, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Favrille, Inc..

Explore the full profile